Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pliant Therapeutics ( (PLRX) ) just unveiled an update.
On March 12, 2025, Pliant Therapeutics’ board of directors adopted a stockholder rights agreement to protect against hostile takeovers by issuing a dividend of one preferred share purchase right for each outstanding share of common stock. This move aims to prevent any entity from gaining control of the company without paying a control premium, ensuring that the board has the opportunity to act in the best interests of all stockholders. The rights become exercisable if a person or group acquires 10% or more of the company’s common stock without board approval, allowing existing stockholders to purchase additional shares at a discount, thus diluting the acquiring party’s stake.
More about Pliant Therapeutics
Pliant Therapeutics is a late-stage biopharmaceutical company focused on developing novel therapeutics for fibrotic diseases. Its lead product candidate, bexotegrast, is an oral small molecule in development for idiopathic pulmonary fibrosis and has received Fast Track and Orphan Drug Designations from the FDA and Orphan Drug Designation from the European Medicines Agency.
YTD Price Performance: -88.10%
Average Trading Volume: 2,440,128
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $95.83M
For detailed information about PLRX stock, go to TipRanks’ Stock Analysis page.